

Appl. No.
Filed

: 09/350,043
: July, 8, 1999

Sub B1
Contd
A1
Cont

an ethoxylated lipid;
an alcohol mixed with the ethoxylated lipid so as to form a penetration enhancer;
an aqueous adjuvant mixed with the penetration enhancer, wherein the aqueous adjuvant comprises *Aloe Vera*, and
a delivery agent mixed with the aqueous adjuvant and the penetration enhancer.

2. (AMENDED) The transdermal delivery system of Claim 1, wherein the ethoxylated lipid is a vegetable or animal oil having at least 20 ethoxylations per molecule.

A2

5. (AMENDED) The transdermal delivery system of Claim 1, wherein about 0.1% to 85% by weight or volume is *Aloe Vera*.

A3

9. (AMENDED) The transdermal delivery system of Claim 1, wherein the delivery agent is selected from the group consisting of capsaicin, Boswellin, non steroidal anti-inflammatory drug, and collagen.

A4
Sub B2

12. (AMENDED) A transdermal delivery system comprising:
an ethoxylated oil;
an alcohol mixed with the ethoxylated oil so as to form a penetration enhancer;
Aloe Vera mixed with the penetration enhancer; and
a therapeutically effective amount of capsaicin or NSAID or both mixed with the penetration enhancer and *Aloe Vera*.

17. (CANCELLED)

18. (CANCELLED)

Sub B3
AS

19. (AMENDED) A transdermal delivery system comprising:
an ethoxylated oil;

Appl. No. : 09/350,043
Filed : July, 8, 1999

Sub B3
cont'd

AS
cont

an alcohol mixed with the ethoxylated oil so as to form a penetration enhancer;
an aqueous adjuvant mixed with the penetration enhancer, wherein the aqueous
adjuvant comprises *Aloe Vera*; and
a therapeutically effective amount of a delivery agent having a molecular weight
of more than 2,000 daltons mixed with the penetration enhancer and aqueous adjuvant.

20. (CANCELLED)

29
21. (AMENDED) The transdermal delivery system of Claim ²⁸~~19~~, wherein the delivery agent
is a collagen or fragment thereof.

30
22. (AMENDED) The transdermal delivery system of Claim ²⁹~~21~~, wherein the collagen has an
approximate average molecular weight from about 2,000 daltons to about 500,000 daltons.

31
23. (AMENDED) The transdermal delivery system of Claim ²⁹~~21~~, wherein the therapeutically
effective amount of collagen by weight or volume is 0.1% to 50.0%.

32
24. (AMENDED) The transdermal delivery system of Claim ²⁹~~21~~, wherein the collagen has an
approximate average molecular weight of about 2,000 daltons and the therapeutically effective
amount by weight or volume is 0.1% to 50.0%.

33
25. (AMENDED) The transdermal delivery system of Claim ²⁹~~21~~, wherein the collagen has an
approximate average molecular weight of about 300,000 daltons and the therapeutically effective
amount is 0.1% to 2.0%.

34
26. (AMENDED) The transdermal delivery system of Claim ²⁹~~21~~, wherein the collagen has an
approximate average molecular weight of about 500,000 daltons and the therapeutically effective
amount by weight or volume is 0.1% to 4.0%.

Appl. No. : 09/350,043
Filed : July, 8, 1999

29. (CANCELLED)

AM
Sub B⁴

30. (AMENDED) A method of making a transdermal delivery system comprising:
providing an ethoxylated oil;
mixing the ethoxylated oil with an alcohol, nonionic solubilizer, or emulsifier so
as to form a penetration enhancer;
mixing the penetration enhancer with an aqueous adjuvant, wherein the aqueous
adjuvant comprises *Aloe Vera*; and
mixing the penetration enhancer and aqueous adjuvant with a delivery agent and
thereby making the transdermal delivery system.

1A8 43 32. (AMENDED) The method of Claim 30, wherein the delivery agent has a molecular
weight greater than 2,000 daltons.

12
35. (NEW) The transdermal delivery system of Claim 1, wherein the delivery agent is a non
steroidal anti-inflammatory drug.

13
36. (NEW) The transdermal delivery system of Claim 35, wherein the non steroidal anti-
inflammatory drug is selected from the group consisting of naproxin, ibuprofen, and aspirin.

14
37. (NEW) The transdermal delivery system of Claim 35, wherein the non steroidal anti-
inflammatory drug is aspirin.